WST

West Pharmaceutical Services' stock has been impacted by several positive events in the past six months. The company reported strong fourth-quarter and full-year 2025 results, driven by double-digit organic revenue growth in its High-Value Product Components. The board approved a $1 billion stock buyback program. The company announced robust first-quarter 2026 results, exceeding expectations, which led to a 13% increase in the stock price. Management also raised its full-year 2026 guidance for both revenue and adjusted EPS. The stock reached a 52-week high of $322.40 on May 7, 2026. A "golden cross" technical signal occurred, indicating a bullish trend. Analysts have upgraded their ratings and raised target prices. Over the last 12 months, the stock price has increased by 35.17%, with a year-to-date return of 6.22%, and a 20.18% increase in the past month.